Skip to content
2000
Volume 25, Issue 18
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Objective

This study aimed to explore the roles of BCL6 and STAT4 in breast cancer, their biological functions, and their relationships with the prognosis of patients with breast cancer.

Methods

Online databases were used to analyze the expression characteristics of BCL6 and STAT4 in breast cancer, as well as the correlation between STAT4 and both the prognosis of breast cancer patients and the biological function of breast cancer cells. BC cell lines, such as MCF7 and MDA-436 cells, were treated with the BCL6 inhibitor TP-021, and STAT4 and BCL6 mRNA expression levels were detected. Sh-RNAs were used to downregulate STAT4 in MCF7 and MDA-436 cells, and their proliferation ability was measured a CCK-8 assay.

Results

BCL6 expression was detected in BC cell lines and tissues, but the expression of STAT4 was downregulated in BC, and the expression level of STAT4 was negatively correlated with patient prognosis. Inhibition of BCL6 can increase the STAT4 level in BC cells and inhibit their proliferation ability . Poor prognosis may be related to the expression of STAT4 and the characteristics of immune cell infiltration in tumor tissues.

Conclusion

BCL6 inhibitors demonstrated therapeutic effects on breast cancer cells through the BCL6-STAT4 pathway.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206364308250410104338
2025-04-18
2025-09-14

  • From This Site

    /content/journals/acamc/10.2174/0118715206364308250410104338
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. CheangM.C.U. ChiaS.K. VoducD. GaoD. LeungS. SniderJ. WatsonM. DaviesS. BernardP.S. ParkerJ.S. PerouC.M. EllisM.J. NielsenT.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.J. Natl. Cancer Inst.20091011073675010.1093/jnci/djp082 19436038
     [Google Scholar]
  3. HankerA.B. SudhanD.R. ArteagaC.L. Overcoming endocrine resistance in breast cancer.Cancer Cell202037449651310.1016/j.ccell.2020.03.009 32289273
     [Google Scholar]
  4. GhetuA.F. CorcoranC.M. CerchiettiL. BardwellV.J. MelnickA. PrivéG.G. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.Mol. Cell200829338439110.1016/j.molcel.2007.12.026 18280243
     [Google Scholar]
  5. SteadM.A. RosbrookG.O. HaddenJ.M. TrinhC.H. CarrS.B. WrightS.C. Structure of the wild-type human BCL6 POZ domain.Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.200864121101110410.1107/S1744309108036063 19052359
     [Google Scholar]
  6. BassoK. Dalla-FaveraR. Roles of BCL6 in normal and transformed germinal center B cells.Immunol. Rev.2012247117218310.1111/j.1600‑065X.2012.01112.x 22500840
     [Google Scholar]
  7. LiuY. BartaS.K. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.Am. J. Hematol.201994560461610.1002/ajh.25460 30859597
     [Google Scholar]
  8. ScottD.W. KingR.L. StaigerA.M. Ben-NeriahS. JiangA. HornH. MottokA. FarinhaP. SlackG.W. EnnishiD. SchmitzN. PfreundschuhM. NowakowskiG.S. KahlB.S. ConnorsJ.M. GascoyneR.D. OttG. MaconW.R. RosenwaldA. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.Blood2018131182060206410.1182/blood‑2017‑12‑820605 29475959
     [Google Scholar]
  9. KünstnerA. WitteH.M. RiedlJ. BernardV. StöltingS. MerzH. OlschewskiV. PeterW. KetzerJ. BuschY. TrojokP. BubnoffN. BuschH. FellerA.C. GebauerN. Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.Haematologica202110781850186310.3324/haematol.2021.279631 34788985
     [Google Scholar]
  10. PintoA.E. AndréS. SilvaG. VieiraS. SantosA.C. DiasS. SoaresJ. BCL-6 oncoprotein in breast cancer: loss of expression in disease progression.Pathobiology200976523524210.1159/000228899 19816083
     [Google Scholar]
  11. BalE. KumarR. HadigolM. HolmesA.B. HiltonL.K. LohJ.W. DrevalK. WongJ.C.H. VlasevskaS. CorinaldesiC. SoniR.K. BassoK. MorinR.D. KhiabanianH. PasqualucciL. Dalla-FaveraR. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.Nature2022607792080881510.1038/s41586‑022‑04906‑8 35794478
     [Google Scholar]
  12. XiaoJ. SunF. WangY.N. LiuB. ZhouP. WangF.X. ZhouH.F. GeY. YueT.T. LuoJ.H. YangC.L. RongS.J. XiongZ.Z. MaS. ZhangQ. XunY. YangC.G. LuanY. WangS.G. WangC.Y. WangZ.H. UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer.J. Clin. Invest.20231334e15835210.1172/JCI158352 36626227
     [Google Scholar]
  13. ZagoritiZ. LagoumintzisG. PerroniG. PapathanasiouG. PapadakisA. AmbrogiV. MineoT.C. TzartosJ.S. PoulasK. Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?J. Neuroimmunol.2018319939910.1016/j.jneuroim.2018.03.008 29576322
     [Google Scholar]
  14. YasuiT. YamamotoT. SakaiN. AsanoK. TakaiT. YoshitomiY. DavisM. TakagiT. SakamotoK. SogabeS. KamadaY. LaneW. SnellG. IwataM. GotoM. InookaH. SakamotoJ. NakadaY. ImaedaY. Discovery of a novel B-cell lymphoma 6 (BCL6)–corepressor interaction inhibitor by utilizing structure-based drug design.Bioorg. Med. Chem.201725174876488610.1016/j.bmc.2017.07.037 28760529
     [Google Scholar]
  15. LambertS.A. JolmaA. CampitelliL.F. The human transcription factors.Cell2018175259859910.1016/j.cell.2018.09.045 30290144
     [Google Scholar]
  16. LiY.F. AltmanR.B. Systematic target function annotation of human transcription factors.BMC Biol.2018161410.1186/s12915‑017‑0469‑0 29325558
     [Google Scholar]
  17. NikkanenJ. LeongY.A. KrauseW.C. DermadiD. MaschekJ.A. Van RyT. CoxJ.E. WeissE.J. GokcumenO. ChawlaA. IngrahamH.A. An evolutionary trade-off between host immunity and metabolism drives fatty liver in male mice.Science2022378661729029510.1126/science.abn9886 36264814
     [Google Scholar]
  18. KerresN. SteurerS. SchlagerS. BaderG. BergerH. CaligiuriM. DankC. EngenJ.R. EttmayerP. FischerauerB. FlotzingerG. GerlachD. GerstbergerT. GmaschitzT. GrebP. HanB. HeyesE. IacobR.E. KesslerD. KölleH. LamarreL. LanciaD.R. LucasS. MayerM. MayrK. MischerikowN. MückK. PeinsippC. PetermannO. ReiserU. RudolphD. RumpelK. SalomonC. ScharnD. SchnitzerR. SchrenkA. SchweiferN. ThompsonD. TraxlerE. VareckaR. VossT. Weiss-PuxbaumA. WinklerS. ZhengX. ZoephelA. KrautN. McConnellD. PearsonM. KoeglM. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.Cell Rep.201720122860287510.1016/j.celrep.2017.08.081 28930682
     [Google Scholar]
  19. SłabickiM. YoonH. KoeppelJ. NitschL. Roy BurmanS.S. Di GenuaC. DonovanK.A. SperlingA.S. HunkelerM. TsaiJ.M. SharmaR. GuirguisA. ZouC. ChudasamaP. GasserJ.A. MillerP.G. SchollC. FröhlingS. NowakR.P. FischerE.S. EbertB.L. Small-molecule-induced polymerization triggers degradation of BCL6.Nature2020588783616416810.1038/s41586‑020‑2925‑1 33208943
     [Google Scholar]
  20. YangF. XiaoY. DingJ.H. JinX. MaD. LiD.Q. ShiJ.X. HuangW. WangY.P. JiangY.Z. ShaoZ.M. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.Cell Metab.202335184100.e810.1016/j.cmet.2022.09.021 36257316
     [Google Scholar]
  21. ZhuoJ. HanJ. ZhaoY. RAB10 promotes breast cancer proliferation migration and invasion predicting a poor prognosis for breast cancer.Sci. Rep.20231311525210.1038/s41598‑023‑42434‑1 37709911
     [Google Scholar]
  22. Fahlquist-HagertC. WittenbornT.R. Terczyńska-DylaE. KastbergK.S. YangE. RallistanA.N. MarkettQ.R. WintherG. FonagerS. VossL.F. PedersenM.K. van CampenN. FerapontovA. JensenL. HuangJ. NielandJ.D. van der PoelC.E. PalmfeldtJ. CarrollM.C. UtzP.J. LuoY. LinL. DegnS.E. Antigen presentation by B cells enables epitope spreading across an MHC barrier.Nat. Commun.2023141694110.1038/s41467‑023‑42541‑7 37907556
     [Google Scholar]
  23. M ScavuzziB. van DrongelenV. KaurB. FoxJ.C. LiuJ. Mesquita-FerrariR.A. Kahlenberg J.M. FarkashE.A. BenavidesF. MillerF.W. SawalhaA.H. HoloshitzJ. The lupus susceptibility allele DRB1*03:01 encodes a disease-driving epitope.Commun. Biol.20225175110.1038/s42003‑022‑03717‑x 35902632
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206364308250410104338
Loading
BCL6 Inhibitors Exhibit Therapeutic Effects on Breast Cancer Cells through the BCL6-STAT4 Pathway
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 25, 1447 (2025); https://doi.org/10.2174/0118715206364308250410104338
/content/journals/acamc/10.2174/0118715206364308250410104338
/content/journals/acamc/10.2174/0118715206364308250410104338
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): BCL6; breast cancer; cell proliferation; immune cell infiltration; STAT4; TP-021

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test